Adenosquamous cell lung cancer is a rare and aggressive form of non-small cell lung cancer that combines features of two different cancer types, requiring specialized treatment approaches and careful management by experienced medical teams.

Understanding How Treatment Works for This Rare Cancer

When someone receives a diagnosis of adenosquamous cell lung cancer, understanding the treatment path ahead becomes crucial. This rare form of lung cancer presents unique challenges because it contains both adenocarcinoma (cancer arising from glandular cells that produce mucus) and squamous cell carcinoma (cancer from flat cells lining the airways) components. The treatment approach focuses on controlling symptoms, potentially slowing disease progression, and maintaining the best possible quality of life for patients.

Treatment choices depend heavily on several factors. The stage of disease at diagnosis plays a major role—whether the cancer is confined to one area of the lung or has spread to lymph nodes or distant organs. Patient characteristics matter too, including overall health status, lung function, and ability to tolerate different therapies. Age alone isn’t necessarily a barrier to treatment, but the presence of other medical conditions can influence which options are safest and most appropriate.

Medical societies and cancer centers have developed standard treatment protocols based on years of research and clinical experience. These established treatments represent the foundation of care. At the same time, researchers continue investigating new therapeutic approaches through clinical trials, offering hope for better outcomes. Some patients may benefit from participating in these studies, which test innovative drugs and treatment combinations not yet widely available.

Standard Treatment Approaches

Surgery remains a cornerstone treatment for patients diagnosed with early-stage adenosquamous lung cancer. When the tumor hasn’t spread beyond the lung, surgical removal offers the best chance for long-term survival. Several types of operations may be considered depending on tumor size and location. Lobectomy, which removes one lobe of the lung containing the tumor, is commonly performed. Segmentectomy removes a smaller portion of lung tissue, while pneumonectomy involves removal of an entire lung in cases where the cancer is more extensive but still operable.

Following surgery, many patients receive additional treatment to reduce the risk of cancer returning. Platinum-based chemotherapy serves as the standard postoperative approach. These treatments combine platinum-containing drugs like cisplatin or carboplatin with other chemotherapy medications. Clinical evidence demonstrates that patients with stage III disease who complete at least four cycles of platinum-based chemotherapy after surgery experience significantly improved survival compared to those who don’t receive this additional treatment.^[1]

The duration of chemotherapy treatment typically extends over several months. Each cycle involves receiving the drugs followed by a recovery period, allowing the body time to heal from side effects before the next treatment. This schedule balances the need to attack cancer cells aggressively while giving normal tissues a chance to recover.

For patients whose cancer has spread or cannot be surgically removed, chemotherapy becomes the primary treatment option. Platinum-based combinations remain the foundation of care for advanced disease. These drugs work by damaging the DNA inside rapidly dividing cancer cells, preventing them from multiplying further. While both adenocarcinoma and squamous cell carcinoma components may be present, the treatment approach considers the tumor as a single entity rather than targeting each component separately.

Side effects from chemotherapy can significantly impact daily life, though they vary from person to person. Common problems include nausea and vomiting, which modern anti-nausea medications can often control effectively. Fatigue represents another frequent complaint, sometimes lasting weeks or months. Hair loss occurs with many chemotherapy regimens, though hair typically grows back after treatment ends. Blood cell counts may drop, increasing infection risk and causing anemia or bleeding problems. Regular blood tests monitor these effects, allowing doctors to adjust dosages or delay treatments when necessary.

Radiation therapy plays an important role for certain patients with adenosquamous lung cancer. High-energy rays target cancer cells in specific areas, potentially shrinking tumors and relieving symptoms. Patients with unresectable disease—meaning surgery isn’t possible due to tumor location or spread—may achieve good local control with radiation. When combined with chemotherapy, radiation can help patients with locally advanced disease achieve longer survival. The treatment usually involves daily sessions over several weeks, with each session lasting only a few minutes.

Targeted Therapies Based on Genetic Changes

A significant advance in lung cancer treatment involves testing tumors for specific genetic mutations that can be targeted with specialized drugs. For patients with adenosquamous carcinoma, this testing becomes particularly important because it may reveal opportunities for more effective treatment with fewer side effects than traditional chemotherapy.

The epidermal growth factor receptor (EGFR) represents one of the most important targets in lung cancer treatment. This protein sits on the cell surface and, when activated, sends signals telling cells to grow and divide. Certain mutations in the EGFR gene cause the receptor to stay “on” constantly, driving uncontrolled cancer cell growth. EGFR tyrosine kinase inhibitors (EGFR-TKIs) block this overactive signaling.

Medications like erlotinib and gefitinib have demonstrated effectiveness in treating advanced adenosquamous lung cancer when EGFR mutations are present. These oral medications work differently from chemotherapy—instead of broadly attacking dividing cells, they specifically target the molecular abnormality driving cancer growth. Patients whose tumors harbor EGFR mutations often respond very well to these drugs, experiencing tumor shrinkage and symptom improvement. The treatment continues as long as it remains effective and side effects stay manageable.^[1]

Side effects from EGFR-TKIs differ from chemotherapy side effects. Skin rash, particularly on the face and upper body, occurs commonly and may indicate the drug is working. Diarrhea affects many patients but usually responds to anti-diarrheal medications. Some people develop dry skin or changes in their nails. These side effects, while bothersome, are generally less severe than chemotherapy-related problems, and most patients continue their normal activities while taking these medications.

Other genetic abnormalities can also be targeted. ALK (anaplastic lymphoma kinase) gene rearrangements occur in a small percentage of lung cancers. Crizotinib, a drug that blocks the abnormal ALK protein, has revolutionized treatment for ALK-positive lung cancers. However, research on crizotinib specifically in adenosquamous carcinoma patients remains very limited, and doctors have less experience using this drug for this rare subtype.^[1]

Emerging Immunotherapy Treatments in Clinical Trials

Immunotherapy represents one of the most exciting developments in cancer treatment over the past decade. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. For adenosquamous lung cancer, immunotherapy shows considerable promise and is actively being studied in clinical trials.

The immune system normally patrols the body looking for abnormal cells to destroy. Cancer cells often evade this surveillance by displaying certain proteins that act like “off switches” for immune cells. The PD-1 (programmed death-1) protein on T cells (a type of immune cell) and its partner PD-L1 (programmed death-ligand 1) on cancer cells create one such checkpoint. When PD-1 and PD-L1 connect, they turn off the T cell’s ability to attack, allowing cancer cells to escape destruction.

Immune checkpoint inhibitors are drugs that block these off switches, reactivating the immune system’s cancer-fighting abilities. Research has shown that PD-L1 expression varies in adenosquamous carcinomas, with interesting patterns. Studies found that the squamous component of these tumors expresses PD-L1 more frequently than the adenocarcinoma component. The squamous portions show similar PD-L1 levels to pure squamous cell lung cancers, while the adenocarcinoma portions resemble pure adenocarcinomas in their PD-L1 expression.^[5]

This discovery has important implications for treatment. Clinical trials testing immune checkpoint inhibitors like pembrolizumab, nivolumab, and atezolizumab have included some patients with adenosquamous carcinoma. Results from a study in China showed that patients with advanced adenosquamous lung cancer who received immune checkpoint inhibitors achieved an objective response rate of 23.7 percent—meaning about one in four patients experienced significant tumor shrinkage. The disease control rate reached 86.8 percent, indicating that most patients benefited from either tumor shrinkage or disease stabilization.^[9]

The relationship between PD-L1 expression levels and treatment response remains under investigation. In the Chinese study, patients whose tumors tested positive for PD-L1 had a response rate of 36.4 percent, while those with PD-L1-negative tumors had no complete or partial responses. However, survival times were similar between the two groups, suggesting that PD-L1 testing alone may not perfectly predict who will benefit from immunotherapy.^[9]

These immunotherapy drugs are typically given by intravenous infusion every two to three weeks. They may be used alone or combined with chemotherapy. Some trials are testing them as initial treatment for advanced disease, while others examine their use after previous treatments have stopped working. The approach of combining immunotherapy with chemotherapy aims to leverage the direct cancer-killing effects of chemotherapy alongside the immune system activation from checkpoint inhibitors.

Side effects from immunotherapy differ substantially from chemotherapy. Because these drugs activate the immune system broadly, they can cause inflammation in various organs. Common problems include fatigue and malaise, which affected over half of patients in clinical studies. Skin reactions, thyroid function changes, and digestive problems occur less frequently. Pneumonitis—inflammation of the lungs—represents a potentially serious complication that requires immediate medical evaluation if breathing difficulties develop. In clinical trials, about 13 percent of patients experienced severe side effects requiring hospitalization or treatment interruption.^[9]

Clinical Trial Phases and What They Mean

Understanding how clinical trials work helps patients make informed decisions about participation. Trials proceed through distinct phases, each designed to answer specific questions about a new treatment.

Phase I trials focus primarily on safety. Researchers test a new drug or treatment approach in a small group of patients, usually 15 to 30 people, to determine safe dosing, identify side effects, and understand how the body processes the drug. These trials accept patients who have usually tried other treatments without success.

Phase II trials examine whether the treatment actually works against cancer. Larger groups of patients, typically 30 to 100 people, receive the treatment at doses determined to be safe in Phase I. Researchers measure tumor response, symptom improvement, and continue monitoring side effects. Promising results in Phase II lead to Phase III testing.

Phase III trials compare the new treatment directly against current standard therapy. These large studies may enroll hundreds or thousands of patients, randomly assigning them to receive either the experimental treatment or standard care. Only treatments showing clear benefits in Phase III trials typically gain approval for widespread use.

For adenosquamous lung cancer specifically, most clinical trials don’t exclusively enroll patients with this subtype due to its rarity. Instead, these patients may qualify for trials accepting all non-small cell lung cancer subtypes. The immunotherapy studies described earlier included adenosquamous patients alongside those with pure adenocarcinoma or squamous cell carcinoma. While this means results may not apply equally to all subtypes, it allows patients with rare cancers access to promising experimental treatments.

Clinical trials conduct research worldwide. Major cancer centers in the United States, Europe, and Asia all run studies testing new treatments for lung cancer. In China, researchers have focused specifically on outcomes for adenosquamous carcinoma patients receiving immunotherapy, contributing valuable data about this rare subtype. Patient eligibility varies by trial but generally includes factors like disease stage, previous treatments received, organ function test results, and overall health status.

Additional Treatment Considerations

Beyond cancer-directed treatments, supportive care plays a vital role in helping patients maintain quality of life. Palliative care focuses on symptom management and comfort rather than curing disease. This doesn’t mean giving up on treatment—palliative approaches work alongside cancer treatments to address pain, breathing difficulties, fatigue, and emotional distress.

For patients with advanced adenosquamous lung cancer, managing respiratory symptoms becomes particularly important. Shortness of breath can result from tumor blocking airways, fluid accumulation around the lungs, or treatment side effects. Interventions might include medications to open airways, procedures to drain fluid, oxygen therapy, or techniques to manage anxiety related to breathing difficulties.

Pain management requires careful attention. Pain may arise from the tumor itself, spread to bones or other sites, or from treatment side effects. A multimodal approach using different types of pain medications, along with non-drug strategies like physical therapy or relaxation techniques, often provides the best relief.

Nutritional support helps patients maintain strength during treatment. Cancer and its treatments can reduce appetite, alter taste, or cause nausea that interferes with eating. Working with a dietitian to identify foods that appeal to the patient and provide needed nutrients supports overall health and treatment tolerance.

Most common treatment methods

• Surgery
  • Lobectomy removes one lobe of the lung containing the tumor
  • Segmentectomy removes a smaller lung section when appropriate
  • Pneumonectomy involves removing an entire lung in extensive cases
  • Surgery offers the best outcomes for early-stage disease that hasn’t spread
• Chemotherapy
  • Platinum-based combinations remain the foundation of treatment
  • At least four cycles after surgery significantly improve survival in stage III patients
  • Used as primary treatment when surgery isn’t possible
  • Common side effects include nausea, fatigue, hair loss, and reduced blood counts
• Targeted therapy
  • EGFR tyrosine kinase inhibitors like erlotinib and gefitinib target specific mutations
  • Effective for advanced disease when EGFR mutations are present
  • Crizotinib targets ALK gene rearrangements but limited data exists for this subtype
  • Oral medications with different side effect profiles than chemotherapy
• Immunotherapy
  • Immune checkpoint inhibitors block PD-1/PD-L1 interactions
  • Studies show 23.7 percent response rate in advanced adenosquamous carcinoma
  • Disease control achieved in 86.8 percent of treated patients
  • Can cause immune-related side effects affecting various organs
  • Being studied in clinical trials worldwide
• Radiation therapy
  • Uses high-energy rays to target cancer cells in specific areas
  • Provides local control for unresectable disease
  • Combined with chemotherapy for locally advanced cases
  • Typically involves daily sessions over several weeks